FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:575-576 February 20, 1997 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The role of digitalis in treating cardiovascular disease has been at the center of the oldest continuing controversy in the history of medicine. Ever since its clinical introduction by William Withering more than 200 years ago,¹ physicians have disagreed fiercely about the drug's efficacy and safety, with some advocating its widespread use and others recommending that its application be severely limited or abandoned entirely. Evidence from clinical studies published during the past decade has heightened the sophistication of the debate, but not diminished its intensity.

Advocates of digitalis have argued that the drug should be used because it has been . . . [Full Text of this Article]

References

Related Letters:

Digoxin in Patients with Heart Failure
Umans V. A., Cornel J. H., Hic C., Soto J., Avendaño C., Vilchez F. G., Böhm M., Zoneraich S., Yusuf S., Gorlin R., Garg R., Packer M.
Extract | Full Text  
N Engl J Med 1997; 337:129-131, Jul 10, 1997. Correspondence

This article has been cited by other articles:

• Ahmed, A., Rich, M. W., Love, T. E., Lloyd-Jones, D. M., Aban, I. B., Colucci, W. S., Adams, K. F., Gheorghiade, M. (2006). Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27: 178-186 [Abstract] [Full Text]  
• Young, J. B. (2005). Whither Withering's Legacy?: Digoxin's Role in Our Contemporary Pharmacopeia for Heart Failure. J Am Coll Cardiol 46: 505-507 [Full Text]  
• Cayley, W. E Jr (2004). Digoxin in chronic heart failure. Fam Pract 21: 469-472 [Full Text]  
• Swynghedauw, B, Charlemagne, D (2002). What is wrong with positive inotropic drugs? Lessons from basic science and clinical trials. Eur Heart J Suppl 4: D43-D49 [Abstract]  
• Blaustein, M. P., Lederer, W. J. (1999). Sodium/Calcium Exchange: Its Physiological Implications. Physiol. Rev. 79: 763-854 [Abstract] [Full Text]  
• Leibovitz, A., Bilchinsky, T., Gil, I., Habot, B. (1998). Elevated Serum Digoxin Level Associated With Coadministered Fluoxetine. Arch Intern Med 158: 1152-1153 [Abstract] [Full Text]  
• Floreani, M., Borea, P. A., Gessi, S., Mosti, L., Fossa, P., Dorigo, P. (1997). A New Milrinone Analog: Role of Binding to A1 Adenosine Receptor in its Positive Inotropic Effect on Isolated Guinea Pig and Rat Atria. J. Pharmacol. Exp. Ther. 283: 541-547 [Abstract] [Full Text]  
• Umans, V. A., Cornel, J. H., Hic, C., Soto, J., Avendano, C., Vilchez, F. G., Bohm, M., Zoneraich, S., Yusuf, S., Gorlin, R., Garg, R., Packer, M. (1997). Digoxin in Patients with Heart Failure. NEJM 337: 129-131 [Full Text]